



health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001, Civitas Building, Pretoria

Reference: 2020/03/13/AMD/EDP/01

**NOTICE: SWITCHING PATIENTS FROM TENOFOVIR 300MG/EMTRICITABINE 200MG BACK ONTO ABACAVIR/LAMIVUDINE AND ZIDOVUDINE 300MG/LAMIVUDINE 150MG DUAL COMBINATION FORMULATIONS**

In 2019, a circular was distributed (*see Reference 2019/06/07/AMD/EDP/01*<sup>1</sup>) recommending that certain patients on Abacavir (ABC) 600mg/Lamivudine (3TC) 300mg and Zidovudine (AZT) 300mg/3TC 150mg dual formulation tablets be switched to Tenofovir (TDF) 300mg/Emtricitabine (FTC) 200mg dual combination tablets. This supply challenge has since been resolved.

There is currently a supply constraint with TDF 300mg/FTC 200mg due to increasing demand. It is therefore recommended that patients who were previously switched to TDF/FTC in 2019, be switched back to their original ABC/3TC or AZT/3TC dual combination tablets.

**Comments may be submitted via e-mail:**

Stock queries:

Ms Maureen Masinge

Tel: 012 395 9683

E-mail: [Maureen.Masinge@health.gov.za](mailto:Maureen.Masinge@health.gov.za)

Clinical queries:

Essential Drugs Programme

E-mail: [SAEDP@health.gov.za](mailto:SAEDP@health.gov.za)

Kind regards

MS KHADIJA JAMALOODIEN

DIRECTOR: AFFORDABLE MEDICINES

DATE: 13/3/2020

<sup>1</sup> Notice: Recommendations for the rational use of abacavir 600mg/lamivudine 300mg and zidovudine 300mg/lamivudine 150mg dual combination formulations